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Abstract
Necrotizing enterocolitis (NEC) is the most common non-congenital disease 
of the gastrointestinal tract in infants born prematurely accounting for 
significant morbidity and mortality.1 Despite nearly seventy years of 
research, the exact etiology of NEC is not fully understood. While several 
nations have incorporated probiotic supplementation into their standard of 
care for high-risk infants, many hospitals in the United States and the 
American Academy of Pediatrics have not. This paper will investigate the 
effect of prophylactic probiotic supplementation on NEC morbidity 
compared to standard nutritional management in very low birth weight 
infants. 
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Necrotizing Enterocolitis (NEC)
• A likely multifactorial disease characterized by necrosis of the bowels 
• Severe cases often require surgical intervention and can progress to 
bowel perforation, pneumoperitoneum, and death2
• The majority of cases occur in very low birth weight (VLBW) infants 
(birth weight < 1500 g)3, affecting up to 12% of this population with up 
to a 30% mortality rate4
• Researchers suggested almost 50 years ago that the intestinal 
microbiome could play a role in the development of NEC after 




A literature search was performed in November 2019, on the PubMed and EBSCO 
Academic Search Ultimate website using the terms “necrotizing” AND “enterocolitis” 
AND “probiotic.”  The term “randomized” was also added to the EBSCO search. The 
results were filtered to display only randomized controlled trials that had been 
published within the last 10 years in the English language. The following exclusions 
were applied which resulted in 7 accepted articles: 
1. Studies that utilized meta-analysis or systemic review
2. Studies that did not specifically assess outcomes on very low birth weight infants 
3. Studies that did not specifically measure the outcome of necrotizing enterocolitis 
4. Studies that assessed the use of probiotic therapy as a treatment modality instead 
of prophylactically  
5. Studies that enrolled participants based on specific pre-existing risk factors
Any clinical trial examining the effect of probiotic supplementation faces an 
increased level of complexity that most other treatment modalities do not. 
Probiotics are not standardized and regulated like many other 
commercially available pharmaceuticals. A researcher must select and 
secure a probiotic culture of verifiable quality so that future researchers 
and clinicians can replicate the intervention. Probiotics are living organisms 
whose viability must be maintained. Mistakes in the management of the 
culture can result in an inconsistent intervention that would not be 
apparent to researchers.
The inadequate statistical power in most of the studies means that there 
was a greater potential for a type II error. It is worth considering whether 
some of the studies which saw a statistically insignificant reduction in NEC 
would have concluded significance if larger populations were enrolled. 
Perhaps the most significant finding from this review is the complete lack 
of reported adverse events attributable to the probiotic intervention. This 
is not to say that probiotic supplementation has no risk whatsoever, but it 
would not be wrong to conclude from these findings that prophylactic 
probiotic supplementation in very low birth weight infants is relatively safe 
in comparison to almost every other procedure or intervention done for 
the benefit of a premature newborn. 
Discussion 
Comparison of Study Designs
Study Design Total N Outcomes Measure Tx Regimen
Braga TD, da Silva 
GA, de Lira PI, de 
Carvalho Lima M.
RCT 231 NEC2, sepsis, death Bifidobacterium breve 
and Lactobacillus casei
Dilli D, Aydin B, 
Fettah ND, et al.
RCT 400 NEC2 and death Bifidobacterium lactis
alone or in combination 
with inulin
Güney-Varal İ, 
Köksal N, Özkan H, 
Bağcı O, Doğan P. 
RCT 110 NEC2, sepsis, death, duration 
of hospitalization, duration of 
TPN, and ≥3 episodes of 
feeding intolerance.
Lactobacillus 







Manzoni P, Meyer 
M, Stolfi I, et al.
RCT 743 NEC2, overall mortality not 
attributable to NEC
Bovine lactoferrin or 
Bovine lactoferrin and 
Lactobacillus 
rhamnosus
Oncel MY, Sari FN, 
Arayici S, et al
RCT 400 NEC2, death, culture proven 
sepsis, feeding intolerance, 
days until full enteral feeding 
and duration of hospital stay
Lactobacillus Reuteri
Sari FN, Dizdar EA, 
Oguz S, Erdeve O, 
Uras N, Dilmen U.
RCT 221 NEC2, death, culture-proven 
sepsis without NEC, grades 3 
or 4 intraventricular 
hemorrhage, feeding 
intolerance, feeding amount 
per week, days to reach full 




Serce O, Benzer D, 
Gursoy T, Karatekin 
G, Ovali F.
RCT 208 NEC2, death, time to reach 
100 mL/kg/day of enteral 
feeding, weight gain per 
week, oxygen dependency at 
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The Effect of Prophylactic Probiotic Supplementation on 
Necrotizing Enterocolitis in Very Low Birth Weight Infants
A definitive conclusion concerning the effectiveness of probiotic 
supplementation for the prevention of NEC cannot be reached with the 
data from this review. However, the results from the analysis arguably 
point more toward the existence of benefit than away from it. Further 
research is needed, particularly in comparing potential efficacy among 
the various species of probiotics. It is recommended that clinicians 
consider the potential benefits in light of the demonstrated safety of this 
intervention when educating parents and caregivers.
Conclusion
Three out of seven studies demonstrated a statistically 
significant reduction in the occurrence of stage ≥2 NEC with 
prophylactic probiotic supplementation, but one of the three 
studies had questionable results due to potential design 
flaws. Of the four trials that did not report a statistically 
significant result, the percentage of patients in the 
intervention group that developed NEC was consistently 
smaller than the placebo group, and two of the four had 
insufficient statistical power to confidently reject the null 
hypothesis. It must also be noted that no two studies 
employed the exact same species of probiotic. 
